DelveInsight has launched a new report on “Hepatic Cirrhosis – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Hepatic Cirrhosis Market Report:
- In 2017, cirrhosis caused more than 1.32 million 95% UI 1.27–1.45) deaths (440,000 [416,000–518,000; 33.3%] in females and 883,000 [838 000–967 000; 66.7%] in males) globally, compared with less than 899,000 (829,000–948,000) deaths in 1990. Deaths due to cirrhosis constituted 2.4% (2.3–2.6) of total deaths globally in 2017 compared with 1.9% (1.8–2.0) in 1990. Despite an increase in the number of deaths, the age-standardized death rate decreased from 21.0 (19.2–22.3) per 100,000 population in 1990 to 16.5 (15.8–18.1) per 100,000 population in 2017.
- Recently in a large secondary care hospital, Hsiang et al, showed that the common primary aetiologies for liver cirrhosis were chronic hepatitis B cirrhosis (37.3%), alcoholic liver disease cirrhosis (24.1%), chronic hepatitis C cirrhosis (22.3%), and non-alcoholic fatty liver disease cirrhosis (16.4%).
- According to Vaz et al the age-standardized incidence was estimated at 23.2 per 100,000 person-years (95% CI 21.3–25.1), 30.5 (95% CI 27.5–33.8) for men, and 16.4 (95% CI 14.3–18.7) for women. When stratified by age, the highest incidence rates were registered at age 60–69 years. Men had a higher incidence rate for most age groups when compared to women.
Key benefits of the report:
- Hepatic Cirrhosis market report covers a descriptive overview and comprehensive insight of the Hepatic Cirrhosis Epidemiology and Hepatic Cirrhosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Hepatic Cirrhosis market report provides insights on the current and emerging therapies.
- Hepatic Cirrhosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Hepatic Cirrhosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hepatic Cirrhosis market.
Got queries? Click here to know more about the Hepatic Cirrhosis Market Landscape.
Hepatic Cirrhosis Overview
Cirrhosis is characterized by fibrosis and nodule formation of the liver secondary to chronic injury, leading to alteration of the normal lobular organization of the liver. Various insults can injure the liver, including viral infections, toxins, hereditary conditions, or autoimmune processes. With each injury, the liver forms scar tissue (fibrosis), initially without losing its function. After a chronic injury, most of the liver tissue becomes fibrotic, leading to loss of function and the development of cirrhosis.
Chronic liver diseases usually progress to cirrhosis. In the developed world, the most common causes of cirrhosis are hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH), while hepatitis B virus (HBV) and HCV are the most common causes in the developing world. Other causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, and chronic right-sided heart failure. Cryptogenic cirrhosis is defined as cirrhosis of unclear etiology.
The dynamics of the Hepatic Cirrhosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Galectin Therapeutics, Pharmicell, Madrigal, CymaBay Therapeutics, Galmed Pharmaceuticals, and others during the study period 2019-2032.
Hepatic Cirrhosis Pipeline Therapies and Key Companies
- Belapectin: Galectin Therapeutics
- Cellgram_LC: Pharmicell
- MGL-3196: Madrigal Pharmaceuticals
- Seladelpar: Cymabay Therapeutics
- Aramchol: Galmed Pharmaceuticals
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hepatic Cirrhosis Patient Share (%) Overview at a Glance
5. Hepatic Cirrhosis Market Overview at a Glance
6. Hepatic Cirrhosis Disease Background and Overview
7. Hepatic Cirrhosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatic Cirrhosis
9. Hepatic Cirrhosis Current Treatment and Medical Practices
10. Unmet Needs
11. Hepatic Cirrhosis Emerging Therapies
12. Hepatic Cirrhosis Market Outlook
13. Country-Wise Hepatic Cirrhosis Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Hepatic Cirrhosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Request for a detailed sample report @https://www.delveinsight.com/sample-request/hepatic-cirrhosis-market
Related Reports:
Hepatic Cirrhosis Pipeline
“Hepatic Cirrhosis Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hepatic Cirrhosis market. A detailed picture of the Hepatic Cirrhosis pipeline landscape is provided, which includes the disease overview and Hepatic Cirrhosis treatment guidelines.
Hepatic Cirrhosis Epidemiology
DelveInsight’s ‘Hepatic Cirrhosis Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Hepatic Cirrhosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/